Remove Medicaid Remove Medicare Remove Quality of Life
article thumbnail

New Tool Helps Predict Stroke Outcome with Higher Accuracy

DAIC

This model aligns with the 2025 Centers for Medicare & Medicaid Services (CMS) initiatives, including value-based care and age-friendly health system measures, while supporting our mission to deliver improved outcomes and quality care for every patient."

Stroke 52
article thumbnail

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

Although prognosis of refractory angina has improved in recent years, patients with refractory angina experience a significantly impaired quality of life with disproportionately high utilization of healthcare services. These observations reflect the great need for new therapies for these patients.

article thumbnail

From the Member Sections | Tackling the Polypharmacy Pandemic in CV Care

American College of Cardiology

Initiatives such as the World Health Organization's "Medication Without Harm" and the Centers for Medicare and Medicaid Services' (CMS) expanded quality measures aim to reduce preventable emergency visits and hospital admissions due to medication-related harm. had one or more severe potential drug-drug interaction.1

article thumbnail

Abstract WP122: Readmission to Acute Care from Inpatient Rehabilitation Among Patients with Acute Ischemic Stroke

Stroke Journal

Introduction:Inpatient rehabilitation (IR) for patients with Acute Ischemic Stroke (AIS) offers improved functional recovery and quality of life. Medicare, 1.17 [1.08-1.26]; 1.43]) or on Medicaid (1.17 [1.08-1.26]; Stroke, Volume 56, Issue Suppl_1 , Page AWP122-AWP122, February 1, 2025. 1.26]; 1.30 [1.18-1.43]),

article thumbnail

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

DAIC

BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.

article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. Treated patients also had reduced major adverse cardiac events and greatly improved quality of life. “We said Peter Altman , PhD.,

CMS 111
article thumbnail

Published Research

Society of Thoracic Surgeons - Research

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)